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Previous work has established that the melanocyte-
specific tyrosinase-related protein-1 (TRP-1) promoter
is regulated positively by the microphthalmia-associ-
ated transcription factor Mitf, acting through the con-
served M box and negatively by the T-box factor Tbx2,
which can bind two “melanocyte-specific elements”
termed the MSEu and MSEi. Both the MSEu and MSEi,
which share a 6-base pair GTGTGA consensus, are also
recognized by a previously unidentified melanocyte-
specific factor, MSF. Here we show using a combination
of DNA binding assays, proteolytic clipping, and anti-
Pax3 antibodies that MSF is indistinguishable from
Pax3, a paired homeodomain transcription factor impli-
cated genetically in melanocyte development and the
regulation of the Mitf promoter. Consistent with Pax3
being able to bind the TRP-1 promoter, Pax3 is ex-
pressed in melanocytes and melanomas, and TRP-1 pro-
moter activity is up-regulated by Pax3. The results iden-
tify a novel role for Pax3 in the expression of TRP-1, and
the potential role of Pax3 in the melanocyte lineage is
discussed.
The development of the melanocyte lineage presents a fasci-
nating opportunity to analyze the complex interplay between
signal transduction pathways and transcription factors, which
underlies development. Because melanocytes are not essential
for viability and variations in pigmentation are obvious (1),
over 70 independent genetic loci have been implicated in the
development or function of these melanin-producing cells. Of
the 20 or so that have been cloned to date, some, such as the
genes encoding tyrosinase or tyrosinase-related protein-1
(TRP-1),1 have a clearly defined function in the genesis of
pigment. On the other hand, genes such as the endothelin B
(2–4) and c-Kit receptors (5), and the microphthalmia (6–8),
Sox10 (9, 10), and Pax3 (11) transcription factors have been
implicated in the developmental pathway leading to the gene-
sis of the mature pigment-producing melanocyte from a non-
pigmented melanoblast precursor cell originating in the trunk
neural crest.
Particularly interesting are mutations affecting the Pax3-
paired homeodomain transcription factor, exemplified by the
splotch allele (11), which expresses a truncated Pax3 protein.
Although splotch homozygotes die in utero, heterozygous
splotch mice exhibit pigmentation defects resulting from the
loss of a proportion of the melanoblasts migrating away from
the neural crest. The loss of melanocytes in splotch mice may be
explained by the fact that Pax3 has recently been shown to
activate expression from the promoter for the gene encoding
the microphthalmia-associated basic helix-loop-helix-leucine
zipper transcription factor (Mitf) (12); mice devoid of functional
Mitf lack all pigment cells, and a decrease in Mitf levels result-
ing from monoallelic loss of Pax3 would account for the pig-
mentation defect exhibited by splotch mice. The ability of Pax3
to regulate expression of Mitf is paralleled by the role of Pax3
in skeletal muscle formation where it is required for expression
of the basic helix-loop-helix transcription factors MyoD, Myf-5,
and myogenin (13, 14), which play essential roles in myogenesis.
The role of Pax3 in regulating mitf expression, and conse-
quently melanocyte development, appears to be relatively well
defined, however, it is not known whether Pax3 might also play
a role in differentiation of melanocytes as characterized by the
expression of the genes involved in the manufacture of the
pigment melanin, a process specific to this cell type.
We have previously characterized the cis-acting require-
ments for expression of the human tyrosinase and mouse
TRP-1 promoters (15–17). Both promoters are dependent on
the activity of Mitf, which acts through an initiator E box in the
tyrosinase promoter (15) as well as via the highly conserved M
box element (17, 18) present in the promoters for the tyrosin-
ase, TRP-1 and TRP-2 genes. TRP-1 expression is also regu-
lated by two additional elements with the sequence GTGTGA
termed the MSEu and MSEi, which appear to act as strong
negative regulatory sequences (16, 19). Both the MSEu and
MSEi are recognized by an unidentified factor termed MSF.
However, point mutational analysis revealed that binding by
MSF did not correlate to repression of the TRP-1 promoter, but
rather may be involved in positive regulation of TRP-1 expres-
sion (16). Instead, repression appears to correspond to binding
by Tbx2 (19), a member of the T-box transcription factor family
(20, 21) expressed in melanoblasts and melanocytes. If Tbx2
acts as the repressor of TRP-1, the question remained as to the
nature of MSF.
Here we demonstrate, using a combination of proteolytic
clipping and DNA binding assays that MSF is in fact Pax3.
Moreover we demonstrate that Pax3 can activate TRP-1 ex-
pression in transfection assays and that Pax3 is expressed in
melanocytes and melanomas. Thus Pax3, which plays an es-
sential role early in melanocyte development, also regulates a
marker of melanocyte differentiation, TRP-1.
MATERIALS AND METHODS
Cell Lines and Transfection Assays—The mouse melanoma cell line,
B16, was grown in RPMI 1640 with 10% fetal calf serum. Transfections
were performed using Fugene reagent (Roche Molecular Biochemicals),
according to the manufacturer’s instructions. Cells were plated at 1 3
104/24 wells/plate 24 h before transfection. A total of 600 ng of DNA was
mixed with 1 ml of Fugene in 60 ml of serum-free medium, left for 15 min
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at room temperature, and then added to the cells. 48 h post-transfec-
tion, cells were washed 2 times with cold phosphate-buffered saline and
harvested using 100 ml of lysis buffer (100 mM potassium phosphate, pH
7.8, 0.2% Triton X-100, 1 mM dithiothrietol). Luciferase assays were
performed using the Promega luciferase assay system with 20 ml of cell
extract according to the manufacturer’s instructions. Luciferase activ-
ity was detected using a microplate luminometer apparatus (MicroLu-
mat Plus, EG&G Berthold). All transfections were repeated using dif-
ferent amounts of DNA, and pCH110 containing the SV40 promoter
driving expression of a LacZ reporter was used as an internal control for
transfection efficiency (1 mg/transfection).
Construction of Reporter Plasmids Used—The parental plasmid used
for all luciferase assays was the pGL3-Basic vector (Promega). The
TRP-1 promoter (2336/1114) and its mutated form LS-MSEu, de-
scribed previously (16), were subcloned as XbaI/HindIII fragments into
the pGL3 vector (NheI/HindIII). The MSEi.M3 mutant was isolated in
three steps by polymerase chain reaction-based mutagenesis and was
cloned as an XbaI/HindIII fragment in the pGL3 vector. Details of the
precise cloning strategy used are available on request.
DNA Binding and Proteolytic Clipping Assays—The band shift as-
says were performed in a final volume of 20 ml containing HEPES (pH
7.9), 10% glycerol, and 112 mM KCl. Nuclear extracts were prepared as
described previously (16). In vitro transcribed/translated (ITT) protein
was made according to the manufacturer’s instructions (Promega TNT
T7 Quick Coupled transcription). Nuclear extracts or ITT Pax3 were
preincubated at 0 °C with 1 mg of poly(dIdCzdIdC) for 10 min before the
addition of 10, 50, or 250 ng of cold competitor DNA. After a further
incubation period of 10 min, approximately 0.5 ng of oligonucleotide
probe, labeled at each end by filling in 59 overhangs with Klenow
polymerase and the appropriate [a-32P]dNTP, was added to the reaction
for a further 20 min before loading onto an 8% polyacrylamide gel (44:1
acrylamide/bisacrylamide ratio) and electrophoresis at 200 V for 1.5 h.
The sequences of double-stranded oligonucleotides used as probes
are as follows: MSEi, 59-ctagaGAATTCACTGGTGTGAGAAGGGATT-
AGTt-39; MSEu, 59-ctagaAAAGCTAACAGAAAATACAAGTGTGACAT-
Tt-39; Pax3, 59-ctagaCACCGCACGATTAGCATCGTCACGCTTCAG-39.
Competitor sequences are described in the figures.
Proteolytic clipping (22, 23) was achieved by adding 10, 100, or 1,000
ng of trypsin or chymotrypsin, or V8 protease to the standard band shift
reaction after 10 min of incubation with the probe and were loaded to
the gel after a further 10 min of incubation at room temperature.
Anti-Pax3 Antibody—The specific anti-Pax3 antibody used in this
study has been described previously (24) and was a kind gift from Dr.
Martine Roussel (St. Jude Children’s Research Hospital, Memphis, TN).
RESULTS
DNA Binding Specificity of MSF—In addition to the M box,
the TRP-1 promoter is regulated by the MSEu and MSEi ele-
ments, which share a GTGTGA motif (16). This sequence is
recognized both by the T-box factor Tbx2 (19) and by a factor
found in all melanocyte and melanoma cell lines tested termed
MSF (16). It was essential to establish the identity of MSF if
the regulation of TRP-1 was to be understood. As a first step,
we examined the precise requirements for sequence recognition
by MSF by using a series of oligonucleotides (Fig. 1A) bearing
specific substitutions in the MSEu and MSEi elements. These
oligonucleotides were used as competitors in DNA binding
band shift assays using either an MSEu or MSEi probe. Using
an MSEu probe, and B16 melanoma cell nuclear extract, a
specific complex corresponding to MSF was observed as de-
scribed previously (Fig. 1B). MSF binding was efficiently com-
peted by the MSEu and also by the MSEi. A point mutation,
pm1, affecting the first base of the GTGTGA motif severely
reduced binding by MSF. Binding was essentially abolished by
mutations at positions 3 and 4 of the MSEu (pm3 and pm4,
respectively), and severely reduced (at least 25-fold) using pm2,
pm5, and pm6, in which bases 2, 5, and 6 of the MSEu are
mutated. Thus, mutation of any of the bases within the MSEu
severely reduces binding by MSF.
We next examined more precisely the requirements for bind-
ing the MSEu by using competitors in which specific residues
were substituted by methylated bases or inosine (Fig. 1C). In
the MSEu.CI competitor, each T residue is substituted with a C
residue, whereas the inosine substitutes for A. The result is a
mutant MSEu in which specific changes have been introduced
into the major groove, although leaving the minor groove un-
changed. Given the severity of the changes to the major groove,
we might have expected the MSEu.CI site not to bind MSF.
However, MSF retained the ability to bind the MSEu.CI oligo-
nucleotide but around 5-fold less efficiently than the wild type
MSEu. In contrast binding to an MSEu in which each G residue
was methylated (MSEu.mG) reduced MSF binding by more
than 25-fold, indicating that the presence of methyl groups in
the major groove of the top strand severely affected binding by
MSF. Surprisingly, on the other hand, methylation of two C
residues on the bottom strand (MSEu.mC), failed to affect
binding by MSF. Taken together these data provide an indica-
tion that MSF binds asymmetrically in the major groove with
the presence of methyl groups on the top strand preventing
DNA binding, whereas methyl groups on the bottom strand
have no effect.
FIG. 1. MSF DNA binding specificity. A, oligonucleotides used as
probes and competitors. All oligonucleotides used contain additional
bases at each end indicated in lowercase letters to facilitate cloning. The
MSEu and MSEi GTGTGA motifs are overlined. The derivatives used in
the competition assays are identical except for the indicated residues
shown in lowercase letters. mG indicates a methylated G residue, and mC
a methylated C residue. I indicates inosine and lowercase within these
elements indicates base substitutions. B-D, band shift assays using the
indicated probes and competitors at either 50 and 250 ng (B), or 10, 50,
and 250 ng (C and D).

























Using the MSEi as a probe (Fig. 1D), we were also able to
show that a similar substitution of T with C, and A with inosine
within the MSEi (MSEi.CI), had only a minor effect on binding
by MSF. As with the MSEu probe, binding by MSF to the MSEi
was also efficiently competed by an oligonucleotide where two
C residues on the bottom strand were methylated (MSEu.mC)
and where a 39-flanking C residue was methylated (MSE-
u.mC2). The results obtained for binding to the MSEi probe are
therefore entirely consistent with those obtained using the
MSEu probe.
MSF Binding to the MSEi Requires an Additional 39 Ele-
ment—The data obtained for the MSEu suggested that MSF
bound asymmetrically within the major groove and that each
base within the MSEu was essential for MSF binding. We have
previously described a mutation of the TRP-1 promoter in
which 4 bases within the MSEi are altered (16). This mutation,
termed LSMSEi, results in up to an 80-fold increase in TRP-1
promoter activity in either melanoma or melanocyte cell lines
(16, 19). Consistent with Tbx2 acting as a repressor of TRP-1
expression, Tbx2 is unable to bind the LSMSEi mutant (19). In
contrast, binding by MSF is relatively efficient, being only
around 5-fold reduced compared with a wild type MSEi (Fig. 2).
The result was surprising, because although each base of the
MSEu was important for MSF binding, mutation of 4 bases
within the MSEi failed to affect binding by MSF more than
5-fold. One possible explanation was that binding to the MSEi
required sequences outwith the core GTGTGA motif. In an
attempt to identify any such auxiliary binding site, we intro-
duced additional mutations into the core MSEi GTGTGA motif
as well as the flanking sequences. The mutants used are shown
in Fig. 3A, and the results of the DNA binding assays obtained
using these mutant forms of the MSEi as competitors is shown
in Fig. 3B. As shown above, binding of MSF to the MSEi is
competed by the LSMSEi mutant around 3–5-fold less effi-
ciently than the wild type MSEi. Introduction of mutations into
sequences 59 to the GTGTGA motif (mutants M1 and M2) failed
to affect binding by MSF. In contrast, mutation of an AT-rich
sequence 39 to the MSEi in mutant M3 resulted in greatly
reduced MSF binding by around 25-fold, indicating that this
region may represent the anticipated auxiliary MSF recogni-
tion element. Mutation of the first 2 bases of the MSEi in
mutant M4 reduced binding by around 3-fold, whereas a mu-
tation affecting the same bases together with the 3 bases im-
mediately 39 to the GTGTGA motif again inhibited binding by
MSF by around 25-fold. However, the M6 mutant, which affects
the 39-flanking sequence alone, binds MSF with only around a
2-fold reduction in efficiency.
In summary, the entire series of DNA binding assays would
indicate that at the MSEu each base is important for binding
with asymmetric recognition of the major groove, whereas at
the MSEi, although bases within the GTGTGA motif are im-
portant, a significant contribution to binding is made at the
39-flanking sequences, most notably by the AT-rich motif af-
fected by the M3 mutation. This pattern of DNA recognition is
extremely reminiscent of DNA binding by members of the
paired homeodomain family, which play key regulatory roles
during development (for review, see Ref. 25). DNA recognition
by the paired domain is complex, with different paired domains
able to recognize different though related sequences. From the
crystal structure of the Drosophila protein Prd (26), it is nev-
ertheless evident that the effects of mutations introduced into
the MSEu would be consistent with recognition of this motif by
a paired domain, whereas the homeodomain (27), which can
cooperate in DNA binding with the paired domain (28), would
be able to target the AT-rich motif 39 to the MSEi GTGTGA
element.
Pax3 Is Expressed in Melanocytes and Melanomas—If MSF
were indeed a member of the paired homeodomain family of
transcription factors, the most likely candidate would be Pax3,
which has been implicated genetically in the regulation of
melanocyte development, both in Splotch mice (11) and in
human Waardenburg syndrome type 1 (29, 30). However, the
genetic defect associated with loss of Pax3 might reflect loss of
melanoblast precursor cells, rather than a specific failure of
Pax3 to regulate gene expression after commitment to the
melanocyte lineage. Moreover, although ectopic expression of
Pax3 can regulate the Mitf promoter and bind the promoter in
vitro, surprisingly, it had not previously been determined
whether Pax3 is in fact expressed in cells of the melanocyte
lineage. Thus, before attempting to determine whether MSF
was related to Pax3, it was essential to establish that Pax3 was
indeed expressed in melanocytes. We therefore performed a
Western blot using the mouse melanocyte cell line melan-a, as
well as the mouse B16 and human 501 melanoma cell lines and
probed with a specific anti-Pax3 antibody. ITT Pax3 was used
as a control. The results (Fig. 4) indicate that Pax3 is expressed
in both the melanocyte and melanoma cell lines, but not in the
unrelated 3T3 cell line, a result confirmed both by reverse
transcription-polymerase chain reaction and Northern blotting
(data not shown).2 The absence of Pax3 in 3T3 cells is in
agreement with our previous work where MSF DNA binding
activity was not detected in 3T3 cells (16). The additional faster
migrating band observed using the B16 melanoma cell line may
represent a degradation product of Pax3.
MSF and Pax3—The fact that Pax3 is expressed in melano-
cytes and melanoma cells added weight to the argument that
MSF and Pax3 were related. Significantly, DNA binding site
selection for high affinity Pax3 recognition sequences (31) iden-
tified a number of sequences with very strong homology to the
MSEu or MSEi including for example AAGTGTGAC, identical
to the MSEu over 9 base pairs, and an 8-base pair sequence
2 Dot Bennett, St. George’s Hospital Medical School, London, per-
sonal communication.
FIG. 2. MSF binds the LSMSEi mutant. Band shift assays using
MSEi probe and the indicated competitors at 10, 50, and 250 ng. The
sequence of the LSMSEi mutation is shown in Fig. 1A.
FIG. 3. MSF binding to the MSEi. A, the sequences of the probes
and competitors used with the MSEi overlined and mutations indicated
as underlined lowercase letters. B, band shift assay using indicated
probes and competitors at 10, 50, and 250 ng.

























identical to the MSEi, TGGTGTGA, which also was located a
short distance upstream from an AT-rich element. Taken to-
gether with the fact that Pax3 is expressed in cells of the
melanocyte lineage, the DNA binding data were consistent
with MSF being Pax3. In addition, by using in vitro tran-
scribed/translated Pax3 in a band shift assay (Fig. 5) together
with the MSEu probe and competing with a selection of the
oligonucleotides used to determine the DNA binding specificity
of MSF shown in Fig. 1, it was evident that Pax3 and MSF
recognized DNA in a very similar fashion. Thus for example,
Pax3 could recognize both the MSEu and MSEi elements, was
less affected by the pm2 mutation than the other point muta-
tions in the MSEu, and bound the mC oligonucleotide but not
the mG competitor, indicating that like MSF, DNA binding by
Pax3 was differentially affected by methylation of the top or
bottom strands of the MSEu binding site.
We also used probes corresponding to either a consensus
Pax3 binding site or the MSEu or MSEi elements to show that
Pax3 could recognize the TRP-1 promoter sequences (Fig. 6A).
No binding was observed using unprogrammed ITT reaction
(not shown).
We next chose to use an alternative approach to investigate
more closely the identity of MSF. To this end, we made use of
a proteolytic clipping assay that is used to identify highly
related DNA-binding proteins (22) and has been used by us
previously to identify the Brn-2 transcription factor in mela-
noma cells (23). In this assay, nuclear extract or in vitro tran-
scribed/translated protein is subjected to increasing concentra-
tions of a proteolytic enzyme and specific cleavage products,
which retain the ability to bind DNA are detected using a band
shift assay and an appropriate radiolabeled probe. The pattern
of DNA bound cleavage products obtained is highly specific for
a given protein, being dependent not only on the precise posi-
tion of specific protease cleavage sites in the primary amino
acid sequence but also on their relative accessibility within the
protein, which is dictated by the protein conformation. A spe-
cific pattern of DNA bound products is therefore diagnostic of a
particular protein.
To investigate the possibility that MSF and Pax3 were iden-
tical, we initially performed band shift assays using a consen-
sus Pax3 binding site as probe and either ITT Pax3 or B16 cell
nuclear extract to assess whether Pax3 DNA binding activity
FIG. 4. Pax3 is expressed in melanocytes and melanoma cell
lines. Western blot using anti-Pax3 antibody and either the melanocyte
cell line, melan-a, or the mouse B16 and human 501 melanoma cell
lines. Also shown are 3T3 cells, used as a negative control, and ITT
Pax3 as a positive control. An equivalent amount of total protein was
loaded for all cell lines.
FIG. 5. Pax3 DNA binding specificity. Band shift assay using ITT
Pax3 and the indicated probes and competitors corresponding to those
shown in Fig. 1A. Competitors were used at 10, 50, and 250 ng.
FIG. 6. MSF and Pax3. Proteolytic
clipping band shift assay using ITT Pax3,
baculovirus-expressed Pax6, or B16 mel-
anoma nuclear extract, and the indicated
probes and proteases. The concentration
of the proteases used was determined em-
pirically to yield partial proteolysis at in-
creasing concentrations. The full se-
quences of the Pax3, MSEi, and MSEu
probes are shown under “Materials and
Methods.”

























was present in B16 nuclear extract. After allowing the protein
to bind the probe, the DNA binding reactions were treated with
limited amounts of either trypsin, chymotrypsin, or V8 prote-
ase. The results obtained are presented in Fig. 6B and demon-
strate clearly that B16 nuclear extracts contain Pax3: first, the
relative migration of the intact complex obtained using ITT
Pax3 and B16 extract is identical; and second, the pattern of
DNA binding complexes obtained following proteolytic treat-
ment using any of the three proteases is identical when com-
paring ITT Pax3 to B16 extract. Because the results from the
proteolytic DNA binding assays indicate that Pax3 is present in
the B16 melanoma cell nuclear extracts, we next compared the
pattern of bands obtained using a consensus Pax probe to those
obtained using an MSEu probe together with B16 cell nuclear
extract and chymotrypsin cleavage (Fig. 6C). Again, the rela-
tive migration and pattern of both the intact and proteolytically
cleaved bands obtained with the Pax and MSEu probes is
identical, and the same as that obtained using ITT Pax3 (com-
pare with Fig. 6B), strongly suggesting that the MSEu is rec-
ognized by Pax3.
The specificity of this assay is highlighted by the fact that the
highly related paired homeodomain factor Pax6 can bind the
MSEi probe, but the Pax6 MSEi complex migrates differently
from those containing MSF or Pax3, and moreover the V8
cleavage pattern is different for Pax6 (Fig. 6D) but identical
when using Pax3 or MSF.
Taken together, the results obtained from the DNA binding
and proteolytic clipping assays are consistent with MSF and
Pax3 being identical.
To confirm that MSF and Pax3 were indeed the same, we
made use of the specific anti-Pax3 antibody used for the West-
ern blot shown in Fig. 4, in a bandshift assay using either an
MSEi or MSEu probe and B16 cell nuclear extract. The results
shown in Fig. 7 demonstrate that DNA binding by MSF to
either probe was strongly inhibited by the anti-Pax3 antibody,
but was unaffected using an anti-Mitf antibody that we have
used in similar assays to inhibit binding by Mitf to the M box
(not shown). Thus, both the proteolytic clipping assays as well
as the antibody supershifts are consistent with MSF and Pax3
being identical.
Pax3 Regulates the TRP-1 Promoter—If MSF and Pax3 are
the same, then we might expect Pax3 to regulate transcription
from the TRP-1 promoter. To address this question, we trans-
fected B16 melanoma cells with a TRP-1 luciferase reporter
extending between 2336 and 1114 (Fig. 8A) either alone or
together with a vector expressing Pax3. The results obtained
demonstrated that increasing the amount of Pax3 expression
plasmid used in the transfection resulted in increasing TRP-1
promoter activity (Fig. 8B) with up to 12-fold activation being
achieved at the highest amount of Pax3 expression vector used.
Activation of TRP-1 was specific because no activation of a
tyrosinase-luciferase reporter was observed (Fig. 8C), consist-
ent with the fact that the tyrosinase promoter lacks binding
sites for Pax3(MSF). To ask whether the MSEu or MSEi were
required for activation by Pax3, we also used reporters in which
the MSEu or MSEi had been mutated. Specifically, the MSEi
mutation used was that affecting the auxiliary Pax3 recogni-
tion site, MSEi.m3, because this mutation does not affect bind-
ing by Tbx2; the MSEu mutant, LSMSEu, fails to bind either
Pax3 or Tbx2 and was used, because we have yet to identify
point mutations that distinguish between binding by these two
proteins at the MSEu. In contrast to the wild type TRP-1
promoter, which was activated by Pax3, neither the MSEi.M3
nor the LSMSEu mutant was affected even at the highest doses
of Pax3 expression vector (Fig. 8, D and E). We conclude that
Pax3 can activate the TRP-1 promoter but that efficient acti-
vation appears to require both the MSEu and MSEi.
Because Pax3 and Sox10, an HMG box protein, have been
reported to activate transcription synergistically in glial cells
(32) and because Sox10, as well as Pax3, is implicated in
melanocyte development (9, 10), we also asked whether Sox10
expression could affect the activation of TRP-1 by Pax3. The
TRP-1 luciferase reporter was transfected into B16 melanoma
cells together with different ratios of vectors expressing Pax3
and Sox10. In no experiment were we able to observe any
FIG. 7. MSF is recognized by anti-Pax3 antibody. Band shift
assays using the indicated MSEi (A) or MSEu (B) probes and B16
melanoma cell nuclear extract. Extract was incubated with either the
anti-Pax3 antiserum or a control anti-Mitf anti-serum for 30 min before
the addition of the probe.
FIG. 8. Pax3 can activate the TRP-1 promoter. A, schematic
diagram showing the TRP-1-luciferase reporter used. B, the wild type
TRP-1 luciferase reporter (300 ng) was transfected into B16 melanoma
cells either alone or together with the indicated amounts of a cytomeg-
alovirus-Pax3 expression vector and assayed for luciferase activity 48 h
post-transfection. C-E, the same as for panel B, but using either a
tyrosinase-luciferase reporter (C) or the full-length TRP-1 promoter
containing either the MSEi.M3 mutation (D) (see Fig. 2A) or the
LSMSEi mutation (E).

























cooperativity between Pax3 and Sox10 on the TRP-1 promoter
(data not shown).
DISCUSSION
We have previously established that the TRP-1 promoter is
regulated by a combination of positive and negative elements
(16, 17). One positive element, the M box, is targeted by Mitf
(33), whereas two additional elements, termed the MSEu and
MSEi, are recognized by the T-box factor Tbx2 and a previously
unidentified DNA-binding protein known as MSF (16, 34). If
the regulation of the TRP-1 promoter was to be fully under-
stood, it was important to establish the identity of MSF. Here
we show, using a combination of proteolytic clipping and DNA
binding assays as well as by using a specific anti-Pax3 anti-
body, that MSF and Pax3 appear to be identical, and Pax3 can
up-regulate TRP-1 promoter activity in co-transfection assays.
We also demonstrate for the first time that Pax3 is expressed in
melanocytes and melanoma cells.
Pax3 has already been identified genetically as playing an
essential role in melanocyte development; mutations in Pax3
can give rise to the Splotch phenotype in mice (11) or Waar-
denburg’s syndrome type-1 in humans (29, 35, 36). Both
Splotch and Waardenburg’s syndrome type-1 are characterized
by a partial loss of neural crest-derived melanocytes that may
be accounted for, at least in part, by a requirement for Pax3 for
the expression of the gene encoding Mitf (12). However, the
ability of Pax3 to bind and activate the TRP-1 promoter sug-
gests an additional role for Pax3 in the regulation of melano-
cyte differentiation. Although the MSEu and MSEi can act as
negative regulatory elements, the experiments presented here
suggest that Pax3 may function as a positive regulator of
TRP-1 expression. For example, the LSMSEi mutation can
result in up to an 80-fold increase in TRP-1 promoter activity
(16, 34), but this mutation failed to affect binding by Pax3 more
than around 5-fold, whereas transfection of a Pax3 expression
vector resulted in increased expression from a reporter gene
driven by the TRP-1 promoter. Consistent with Pax3 not being
responsible for repression of the TRP-1 promoter in melanocyte
or melanoma cell lines, previous point mutational analysis of
the MSEu and MSEi demonstrated that recognition of the
MSEu and MSEi by Tbx2 correlated with transcriptional re-
pression (34). Taken together, these data suggest that at the
MSEu and MSEi, Tbx2 may repress and Pax3 activate TRP-1
expression. In addition, although Tbx2 and Pax3 DNA binding
specificity are distinct, for example Pax3 but not Tbx2 can bind
the LSMSEi mutant, they clearly require overlapping se-
quences. As such it seems likely that binding by Pax3 and Tbx2
is mutually exclusive. What determines whether any given
binding site is recognized by Pax3 or Tbx2 at any particular
time will be determined by several factors including, the rela-
tive concentrations of each factor within the cell, and the na-
ture of any regulation dictated by the activity of specific signal
transduction pathways. At the moment, virtually nothing is
known of the factors governing the activity or expression of
either Tbx2 or Pax3.
We have shown here that Pax3 is expressed in melanocytes
as well as melanoma cell lines. Northern blot analysis2 has also
established that Pax3 is expressed both in melanoblasts and in
cells that have the characteristics of melanoblast precursors.
TRP-1, and Mitf, on the other hand are expressed in both
melanoblasts and melanocytes, but are not expressed before
commitment to the melanocyte lineage. Thus during develop-
ment, the expression of Pax3 alone is clearly insufficient to
allow TRP-1 or Mitf to be expressed. Because Pax3 has also
been demonstrated to up-regulate the Mitf promoter, some
mechanism must operate to prevent Pax3 from inappropriately
activating the Mitf and TRP-1 promoters in melanoblast pre-
cursor cells. One possibility is that in melanoblast precursor
cells, Pax3 lacks an essential cofactor to enable it to activate
transcription. Alternatively, because Pax3 has been shown to
possess domains that mediate either transcription activation or
transcription repression (37), it is also possible that Pax3 acts
to repress transcription in pre-melanoblasts, but activates
transcription after the transition to a melanoblast. Such a
switch would require either that Pax3 is regulated by specific
signal transduction pathways and/or that there is selective
recruitment of co-factors to Pax3 to mediate its transcription
activation/repression functions. Although it is not known how
Pax3 is regulated, it has recently been shown that Pax3 can
interact with HIRA, a factor implicated in chromatin modula-
tion and a homologue of Saccharomyces cerevisiae transcrip-
tional co-repressors (38). This observation would suggest that
one role of Pax3 is to organize the chromatin structure across
Pax3 target promoters, though whether the interaction be-
tween Pax3 and HIRA results in a positive or negative regula-
tion of transcription is unclear.
It is also possible that it is the level of Pax3 expression per se
that is the critical factor with the amount of Pax3 protein
present in a cell needing to exceed a threshold before activation
of the Mitf promoter can occur. This may be particularly rele-
vant because melanoblasts express higher levels of Pax3 than
melanoblast precursors.2 This situation appears to occur dur-
ing muscle development where Pax3 is required for the expres-
sion of MyoD (13, 14). Particularly interesting is the observa-
tion that whereas cells derived from dissociated neural tube
normally express Pax3, they are induced to undergo myogen-
esis by infection with a retrovirus expressing Pax3 (14). This
result suggests that the ability of Pax3 to induce myogenesis is
normally suppressed by an inhibitor and that elevating Pax3
levels overcomes repression and leads to myogenesis. The na-
ture of the repressor is unknown, but it may be that a similar
mechanism operates to prevent Pax3 from inducing TRP-1 or
Mitf expression in melanoblast precursor cells. Our future
work will attempt to address this issue.
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